OIPE IAP41
JUN 21 2006
PATENT & TRADEMARK OFFICE

Figure 1



Figure 2

PEP1	IPVL**DE**N**GLF**AP	[SEQ ID NO 1]
PEP2	WGLDY**E**R**G**N**Y**EE	[SEQ ID NO 2]
PEP3	DALAV**D**QM**G**R**F**G	[SEQ ID NO 3]
PEP4	VLVG**E**K**GLF**EGG	[SEQ ID NO 4]
PEP5	EALVL**D**TN**GL**MS	[SEQ ID NO 5]
PEP6	ADRTQ**GL**GWGAS	[SEQ ID NO 6]
PEP7	EEVGSILY**GL**GG	[SEQ ID NO 7]
CONSENSUS	**DE-GLF**	[SEQ ID NO 8]

Figure 3


CONTROL
4.91 (4%)
PEP4
8.82 (33%)
PEP5
11.44 (35%)
PEP3
8.35 (34%)
PEP6
10.00 (33%)
PEP7
14.86 (48%)
PEP2
12.63 (36%)
PEP1
19.81 (45%)
FL1-H
Counts

Figure 4


% Inhibition
80
60
40
20
0
PEP1
PEP7
PEP3
PEP4
PEP2
PEP6
PEP5
Control
E. coli clones

Figure 5


LOS
PEP 1 (CGPIPVLDENGLFAPGPC)
Control peptide (CKSNPIHIIKNRRNIPC)
% inhibition
100
50
0
-50
-100
0.1
0.5
1
Concentration of peptide (mg/ml)


Octa-MAP 1
(CGPIPVLDENGLFAPGPC)
Octa-MAP control
(CGPEARDEGTITLERGPC)
OD 410nm
0
0.5
1
1.5
2
0
100
200
300
400
MAb 2C7 concentration (ng/ml)

Figure 6


Tetra-MAP1 (CGPIPVLDENGLFAPGPC)
Octa-MAP1
PEP1
Tetra-MAP (Control) (CGPEARDEGTITLERGPC)
Octa-MAP (Control)
Purified LOS
% Inhibition
125
100
75
50
25
0
0.01
0.1
1
10
100
Concentration (µM)

Figure 7

Figure 8


A. OCTA-MAP1
n=8
B. LOS (positive control)
n=4
C. FREUND'S ADJUVANT (negative control)
n=4
D. octa-MAP CONTROL (unrelated peptide, [negative control])
n=4
Anti-LOS (IgG; µg/ml)
Weeks
=boost

Figure 9


15
10
5
0
IgG anti-LOS (µg/ml)
0
3
7
10
12
Weeks
Octa-MAP1
LOS (positive control)
Freund's adjuvant (negative control)
octa-MAP control (unrelated peptide, [negative control])

Figure 10



* $p < 0.001$; comparing response to Octa-MAP1 vs negative controls

Figure 11


15
10
5
0
IgM anti-LOS (µg/ml)
0
3
7
10
12
weeks
Octa-MAP1
LOS (positive control)
Freund's adjuvant (negative control)
Octa-MAP control (unrelated peptide, [negative control])

Figure 12


Strain 15253
Strain 15253 lgtG
% survival
250
200
150
100
50
0
A. mAb 2C7
B. Normal mouse serum
C. Post-octa-MAP1 (pooled serum, week 7-11, 1 mouse)
D. Post-LOS (pooled serum, week 7-11, 1 mouse)
E. Post-Adjuvant (pooled serum, week 7-11, 1 mouse)
F. Post-MAP control (pooled serum, week 7-11, 1 mouse)
Antibody source

Figure 13


100
50
0
-50
-100
% killing
0
1
2
3
4
5
6
Antibody concentration (µg/ml)
Post Octa-MAP1,
3 separate mouse sera
mAb 2C7 dilutions